November is Diabetes Awareness Month or National Diabetes Month. In this article, we will take a look at all of the new guidelines, therapies and innovations that have been introduced since Diabetes Awareness Month 2021.
Below is a list of various Diabetes-related clinical practice guidelines that were published between National Diabetes Month 2021 and National Diabetes Month 2022.
Other Diabetes-Related Guidelines
- Standards of Care in Diabetes
- Updated regularly by the American Diabetes Association (ADA)
- Painful Diabetic Neuropathy
- Published December 2021 by the American Academy of Neurology (AAN)
- Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes
- Published January 2022 by the American Heart Association (AHA)
- Exercise/Physical Activity in Individuals with Type 2 Diabetes
- Published January 2022 by the American College of Sports Medicine (ACSM)
- Heart Failure: An Underappreciated Complication of Diabetes
- Published June 2022 by the American Diabetes Association (ADA)
- Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings
- Published June 2022 by the Endocrine Society (ES)
- Management of Hyperglycemia in Type 2 Diabetes
- Published September 2022 by the American Diabetes Association (ADA) & European Association for the Study of Diabetes (EASD)
- Developing a Diabetes Mellitus Comprehensive Care Plan
- Published September 2022 by the American Association of Clinical Endocrinologists (AACE)
- Diabetes Management in Chronic Kidney Disease (CKD)
- Published October 2022 by the American Diabetes Association (ADA) & Kidney Disease Improving Global Outcomes (KDIGO)
2022 has been a relatively quiet year in terms of new FDA approvals in the diabetes space. Many of the existing diabetes medications, such as the SGLT2 inhibitors, are looking towards new indications for heart failure, CVD risk reduction, CKD and similar. While the quantity of new approvals may have been somewhat lackluster, there were two important additions since last year’s Diabetes Awareness Month.
May 2022 – Mounjaro | Eli Lilly –> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
June 2022 – Beovu | Novartis –> Treatment of diabetic macular edema (DME)
There was also a biosimilar to Lucentis approved, Cimerli (Coherus BioSciences), which includes indications for diabetes macular edema.
As we look ahead towards National Diabetes Month 2023, we can almost certainly expect new and updated clinical guidelines from the American Diabetes Association, as they frequently release a yearly update to their Diabetes Standards of Care in December or January. We also expect new Hypoglycemia Guidelines from the Endocrine Society later this year, as well as updates Diabetes and Pregnancy Guidelines in 2023. AMDA (PALTC) is prepping a new update to their Diabetes in Post-Acute and Long-Term Care Guideline as well. As this is just the tip of the iceberg as far as new Diabetes Guidelines in 2023.
Also on the horizon between now and Diabetes Awareness Month 2023 we anticipate new approvals for Type 1 Diabetes, such as Teplizumab from Provention Bio. Early next year we may see an expanded indication for an existing product, Eyelea (Regeneron), in Diabetic Retinopathy.
Copyright © 2022 Guideline Central, All rights reserved.